US 12,083,133 B2
Use of cholecalciferol as adjuvant in the treatment of muscular dystrophies
Silvia Trasciatti, Vecchiano (IT)
Assigned to ABIOGEN PHARMA SPA, Pisa (IT)
Appl. No. 18/552,908
Filed by ABIOGEN PHARMA SPA, Pisa (IT)
PCT Filed Mar. 25, 2022, PCT No. PCT/IB2022/052742
§ 371(c)(1), (2) Date Sep. 28, 2023,
PCT Pub. No. WO2022/208256, PCT Pub. Date Oct. 6, 2022.
Claims priority of application No. 102021000007655 (IT), filed on Mar. 29, 2021.
Prior Publication US 2024/0100070 A1, Mar. 28, 2024
Int. Cl. A61K 31/593 (2006.01); A61P 21/00 (2006.01)
CPC A61K 31/593 (2013.01) [A61P 21/00 (2018.01)] 9 Claims
 
1. A method of treating muscular dystrophy, the method comprising the step of
administering to patients in need thereof a therapeutically effective amount of cholecalciferol as an active agent or adjuvant in the regeneration of muscle tissue, wherein said therapeutically effective amount of cholecalciferol is a dose of 14.2 μg/kg, or 560 IU/kg.